Hearing Practitioner Australia·Regulatory·Tinnitus·5d agoFDA approves BosSTENT trial for pulsatile tinnitusIf the BosSTENT pivotal trial succeeds, it could establish the first purpose-built interventional device for venous sinus stenosis–related pulsatile tinnitus, expanding the treatment pathway beyond audiology into neurovascular care.
MedWatch·Industry news·Business & finance·9d agoNew AI platform and Asia push to keep Sonova ahead of Demant: “We will continue to take share”Sonova's declared AI platform investment and Asia expansion signal a likely acceleration in AI-driven hearing aid features and increased global market competition, which could shape product availability and pricing for clinics worldwide.+Save
Hearing Review·Product announcement·OTC / consumer·10d ago· press releaseYeasound Launches Robin CIC60, an OTC Completely-in-Canal Hearing Aid with Bluetooth StreamingThe Robin CIC60 adds Bluetooth streaming and a hardware remote to the OTC CIC category, potentially lowering the technology and discretion barrier for mild-to-moderate hearing loss adults who self-fit.+Save
Hearing Review·Financial report·Cochlear implants·11d agoEnvoy Medical Reports Q3 2026 Results, Advances Acclaim Cochlear Implant Trial Toward Key MilestonesProgress toward FDA approval of the fully implanted Acclaim cochlear implant could expand treatment options for patients who prefer a device with no external components.+Save
PU¶PubMed·Journal article·Tinnitus·2w agoEarly Post-Market Surveillance of Bimodal Neuromodulation for TinnitusClinicians fitting or referring patients for Lenire should review the emerging real-world adverse event and efficacy data from MAUDE to counsel patients accurately, though practice-changing conclusions require full review of the published findings.+Save
Hearing Review·Product announcement·OTC / consumer·7w agoLegato Frames Now Available in the US, Combining AI Hearing Technology With Prescription EyewearThe integration of OTC hearing aids into prescription eyewear represents a growing convergence of consumer tech and hearing healthcare that could influence patient expectations and referral patterns.+Save
Hearing Tracker·Industry news·OTC / consumer·8w agoMeta Smart Glasses to Get FDA-Cleared OTC Hearing Aid FeatureMeta entering the FDA-cleared OTC hearing aid market via consumer smart glasses signals a major convergence of consumer tech and audiology, with potential to reshape patient acquisition pathways and competitive dynamics for hearing care professionals.+Save
Hearing Health Matters·Product announcement·OTC / consumer·8w agoMeta AI Glasses to Add FDA-Cleared OTC Hearing Aid FeatureFDA-cleared hearing aid software embedded in mainstream consumer eyewear from a major tech company represents a significant expansion of the OTC hearing aid market and could shift where and how mild-to-moderate hearing loss is addressed.+Save
Hearing Health Matters·Industry news·OTC / consumer·8w agoMeta AI Glasses to Add FDA-Cleared OTC Hearing Aid FeatureA major consumer-tech brand entering the FDA-cleared OTC hearing aid space with a wearable already in millions of hands could significantly accelerate consumer self-management of mild-to-moderate hearing loss and reshape patient pathways into audiology clinics.+Save
PU¶PubMed·Journal article·OTC / consumer·8w agoExtremely High Fitting Range and Dangerous Levels Permitted by the Current FDA Guidelines for OTC Hearing Aids and the Need to Consider RECDsAudiologists fitting or advising patients on OTC devices should be aware that current FDA output limits may be unsafe for small ear canals (e.g., children or adults with smaller canals); advocating for RECD-based verification remains best practice.+Save
Hearing Review·Product announcement·OTC / consumer·8w agoEssilorLuxottica Launches Nuance Audio Plus Hearing GlassesHearing glasses from a major optical brand represent a growing convergence of eyewear and hearing technology that could reshape how mild-to-moderate hearing loss is addressed outside traditional audiology channels.+Save
Hearing Review·Journal article·Cochlear implants·2mo agoStudy Supports Expanding Pediatric Cochlear Implant Candidacy to Younger Ages and Residual HearingThis multicenter evidence supports advocating for earlier cochlear implant referral in infants under 12 months and in children with residual hearing; audiologists should document candidacy discussions in light of evolving evidence, but FDA criteria remain unchanged until...+Save
Hearing Health Matters·Blog·Cochlear implants·2mo agoFDA Expands Pediatric Cochlear Implant Candidacy: What’s Changed?Audiologists evaluating pediatric cochlear implant candidates should review the updated FDA candidacy criteria, as children who were previously ineligible — including younger ages and broader hearing loss profiles — may now qualify for earlier intervention.+Save
PU¶PubMed·Journal article·OTC / consumer·2mo agoFrom policy debate to empirical evidence: a proof-of-concept bibliometric and LLM-assisted abstract-level content analysis of OTC hearing aid research before and after FDA regulationThis is a methods paper demonstrating a bibliometric + AI approach to track OTC hearing-aid research trends; no clinical practice change is indicated, but the mapped evidence gaps may help audiologists anticipate where OTC research is heading.+Save
Hearing Review·Product announcement·OTC / consumer·3mo agoJabra Enhance Launches M Series FDA-Cleared Self-Fitting Hearing AidsNo actionable clinical practice change; this is a DTC product launch that expands the OTC/self-fitting market but introduces no new clinical guidance for audiologists.+Save
Hearing Tracker·Product announcement·OTC / consumer·3mo agoJabra Enhance Launches New M Series of Self-Fitting OTC Hearing AidsThe M Series expands the OTC hearing aid market with a tiered rechargeable lineup, increasing consumer choice and potentially drawing more price-sensitive patients away from clinic-dispensed devices.+Save
MedWatch·Industry news·OTC / consumer·3mo agoSamsung gets FDA approval – takes leap into US OTC marketSamsung's FDA-cleared entry into the OTC hearing aid market signals accelerating big-tech competition that could reshape consumer expectations and referral dynamics across the entire audiology profession.+Save
PU¶PubMed·Journal article·OTC / consumer·3mo agoOver-the-counter hearing aids and integrated health-monitoring sensors: a review of clinical evidence and implementationAudiologists should stay informed about OTC hearing aid clinical evidence gaps and emerging sensor integration, as these developments directly affect patient counseling, fitting workflows, and clinic business models.+Save
Hearing Practitioner Australia·Industry news·OTC / consumer·3mo agoFDA clears Samsung Galaxy Buds Hearing Aid feature using NAL-NL2 for fittingNo immediate practice change is required; however, clinicians should anticipate patient inquiries about Samsung OTC hearing aids and be prepared to discuss their appropriate candidacy (mild-to-moderate perceived loss only) relative to professionally fitted devices.+Save
Hearing Review·Financial report·Business & finance·3mo agoFennec Pharmaceuticals Reports 78% Revenue Jump as Pedmark Demand Reaches Record HighRecord adoption of the only FDA-approved otoprotective agent for pediatric cisplatin patients signals growing integration of hearing-preservation protocols in pediatric oncology, which has downstream implications for audiology referral volume and counseling practices.+Save
Hearing Review·Regulatory·Cochlear implants·3mo agoAdvanced Bionics Receives FDA Approval for Expanded Cochlear Implant Candidacy Criteria in SSD and AHLClinicians evaluating adults or children with single-sided deafness (SSD) or asymmetric hearing loss (AHL) can now consider Advanced Bionics cochlear implants as an FDA-approved option under expanded candidacy criteria; referral pathways and candidacy checklists should be...+Save
PU¶PubMed·Journal article·Research (general)·4mo agoRestoration, Not Bypass: Otoferlin Gene Therapy and a New Era in Hearing Loss TreatmentAudiologists should be aware that FDA-approved otoferlin gene therapy (Otarmeni) is now a biological treatment option for patients with confirmed biallelic OTOF-associated SNHL; refer eligible patients to specialized otolaryngology or gene therapy centers for evaluation.+Save
Hearing Health Matters·Press release·Vestibular·4mo agoSound Pharmaceuticals Completes Enrollment in Phase 3 SPI-1005 Study for Ménière’s DiseaseIf Phase 3 results are positive, SPI-1005 could become the first FDA-approved oral pharmacotherapy specifically targeting Ménière's disease, potentially shifting treatment paradigms for audiologists and otolaryngologists.+Save
Hearing Health Matters·Press release·Cochlear implants·4mo agoNew Cochlear Osia 3 Sound Processor Brings Rechargeable Technology and Enhanced ConnectivityThe Osia 3 expands the rechargeable bone-anchored hearing system market, which may influence device selection conversations in clinics that fit patients with conductive or single-sided deafness.+Save
Hearing Review·Regulatory·Regulatory & legal·6mo agoFDA Grants De Novo Classification to TytoCare’s AI Otoscopy ToolClinicians should note this regulatory milestone as the first FDA-cleared AI otoscopy video analysis tool for eardrum bulging detection, but evidence of clinical accuracy and workflow impact in audiology settings is not yet established from this announcement alone.+Save
Hearing Practitioner Australia·Press release·Regulatory & legal·6mo agoAustralian-developed Earflo cup receives FDA Clearance for otitis mediaA non-surgical, non-pharmacological device option for otitis media with effusion could expand the toolkit available to audiologists and ENTs managing middle ear conditions, particularly in paediatric populations.+Save
Hearing Review·Industry news·Research (general)·6mo agoFDA Grants Accelerated Approval to Otarmeni Gene Therapy for OTOF-Related Hearing LossAudiologists should be aware that Otarmeni is now FDA-approved for OTOF-related hearing loss and begin familiarizing themselves with candidate identification (genetic testing referral pathways) and post-treatment audiological monitoring protocols, though prescribing authority...+Save
Hearing Tracker·Regulatory·Regulatory & legal·7mo agoFDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing LossAudiologists and ENT teams treating patients with the relevant genetic form of hearing loss should become familiar with Otarmeni's approved indication and refer eligible patients to gene therapy specialists; this is a practice-changing regulatory milestone.+Save
The Hearing Review YouTube·Podcast·OTC / consumer·2y agoOTC Hearing Aids and How FDA Rules Might Change Hearing Care, with Dr Tom PowersAudiologist Thomas Powers, PhD, and Hearing Review Editor Karl Strom discuss four key aspects of the proposed FDA OTC hearing aid regulations, including output limits and return-for-credit policies.+Save
The Hearing Review YouTube·Video·Public health & policy·2y agoUpdate from Hearing Loss Association of America (HLAA) Executive Director Barbara KelleyHLAA Executive Director Barbara Kelley updates listeners on the organization's advocacy work across FDA, FTC, FCC, HHS, NIDCD, and other hearing healthcare stakeholders.+Save